

**SEPTEMBER 22, 2016 – THURSDAY MORNING MEET THE EXPERT SESSIONS**

<b>7-8 am</b>	<b>Antiphospholipid Antibody ELISA Tests: Technical Aspects and Interpretation</b> Maria Laura Bertolaccini (UK) Room1	<b>Antiphospholipid Antibody ELISA Tests: Technical Aspects and Interpretation (Turkish)</b> Bahar Artim Esen (Turkey) Room2	<b>Lupus Anticoagulant Test: Technical Aspects and Interpretation</b> Ian Mackie (UK) Room3	<b>Lupus Anticoagulant Test: Technical Aspects and Interpretation (Turkish)</b> Reyhan Diz Kucukkaya (Turkey) Room4
---------------	------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------

**SEPTEMBER 22, 2016 – THURSDAY MORNING SESSIONS**

<b>MAIN SESSION 1</b> Origin of Antiphospholipid Antibodies		<b>DEEP DIVE SESSION 1</b> Antiphospholipid Syndrome Treatment Trends Task Force Report	
<b>Moderators</b>	Philip G de Groot (Netherlands), Ender Terzioğlu (Turkey), Rohan Willis (USA)	<b>Moderators</b>	Danieli Andrade (Brazil), Maria Tektonidou (Greece)
<b>Room</b>	<b>Hall A</b>	<b>Room</b>	<b>Hall B</b>
<b>8.00 am</b>	<b>Introduction and the Role of Innate/Adaptive Immunity in aPL Production</b> Rohan Willis (USA)	<b>8.00 am</b>	<b>Introduction &amp; Summary of the 2013 Task Force Report</b> Maria Tektonidou (Greece)
<b>8.25 am</b>	<b>The Role of Infection in aPL Production</b> Miri Blank (Israel)	<b>8.10 am</b>	<b>Is There a Role for Anti-peptide Therapy in APS?</b> Anisur Rahman (UK)
<b>8.50 am</b>	<b>Microbiota and APS</b> Martin Kriegel (USA) (Online Presentation)	<b>8.30 am</b>	<b>What is New in Anti-complement Therapy in APS?</b> Danieli Andrade (Brazil)
<b>9.15 am</b>	<b>Natural Antibodies</b> Philip G de Groot (Netherlands)	<b>8.50 am</b>	<b>Is Mechanistic Target of Rapamycin (mTOR) Inhibition an option in APS?</b> Guillaume Canaud (France)
<b>9.40 am</b>	<b>Group Conclusions</b>	<b>9.10 am</b>	<b>Statins in APS – Where do we stand?</b> Maria Cuadrado (UK)
		<b>9.25 am</b>	<b>Other Potential Future Treatment Targets in APS</b> Maria Gerosa (Italy)
		<b>9.40 am</b>	<b>Closing Remarks and Future Directions</b> Danieli Andrade (Brazil)
<b>9.45 am</b> <b>10.30 am</b>	<b>Coffee Break, Exhibition, and Poster Discussions</b>	<b>9.45 am</b> <b>10.30 am</b>	<b>Coffee Break, Exhibition, and Poster Discussions</b>

<b>MAIN SESSION 2</b> Mechanisms of Antiphospholipid Antibody-mediated Thrombosis		<b>DEEP DIVE SESSION 2</b> International & National Collaborative Research Efforts in Antiphospholipid Syndrome	
<b>Moderators</b>	Ahmet Gul (Turkey), Steve Krilis (Australia), Rohan Willis (USA)	<b>Moderators</b>	Doruk Erkan (USA), Ronald Derksen (Netherlands)
<b>Room</b>	<b>Hall A</b>	<b>Room</b>	<b>Hall B</b>
<b>10.30 am</b>	<b>General Review - aPL-mediated Thrombosis</b> Rohan Willis (USA)	<b>10.30 am</b>	<b>APS ACTION 6-year Anniversary &amp; “Hydroxychloroquine Trial”</b> Doruk Erkan (USA)
<b>10.50 am</b>	<b>The Role of Post-Translational Modification of <math>\beta_2</math>GPI in aPL-mediated Thrombosis</b> Steve Krilis (Australia)	<b>11.00 am</b>	<b>Strategies to Recruit Patients for Rare Diseases, Curbside Consultation, and Immunity</b> Oral Alpan (USA)
<b>11.10 am</b>	<b>Cell Signaling Pathways in aPL-mediated Thrombosis</b> Philip G de Groot (Netherlands)	<b>11.30 am</b>	<b>Update on European Forum on Antiphospholipid Antibodies</b> Denis Wahl (France)
<b>11.30 am</b>	<b>The Central Role of Inflammation in aPL-mediated Thrombosis</b> Jason Knight (USA)	<b>11.50 am</b>	<b>Lessons Learned from a National APS Registry</b> Ljudmila Stojanovich (Serbia)
<b>11.50 am</b>	<b>The Role of Coagulation Pathways in aPL-mediated Thrombosis</b> Hannah Cohen (UK)	<b>12.10 pm</b>	<b>Group Conclusions</b>
<b>12.10 pm</b>	<b>Group Conclusions</b>		
<b>12.15 pm</b> <b>1.30 pm</b>	<b>Lunch Break &amp; Satellite Symposium</b>	<b>12.15 pm</b> <b>1.30 pm</b>	<b>Lunch Break &amp; Satellite Symposium</b>
<b>A Joint Session with Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)</b>			

**SEPTEMBER 22, 2016 – THURSDAY NOON SATELLITE SYMPOSIUM**

**The Future of Antiphospholipid Antibody Testing**

<b>Moderators</b>	<b>Maria Laura Bertolaccini (UK), Ian Mackie (UK)</b>
<b>Room</b>	<b>HALL A</b>
<b>12.15 pm</b>	<b>Opening Remarks</b> Maria Laura Bertolaccini (UK), Ian Mackie (UK)
<b>12.30 pm</b>	<b>The Value of Microparticle Chemiluminescence Technology for aPL Testing</b> Vittorio Pengo (Italy)
<b>12.45 pm</b>	<b>β<sub>2</sub>-Glycoprotein-I Domain-I in the Assessment of Thrombosis Risk in APS</b> Anisur Rahman (UK)
<b>1.00 pm</b>	<b>Potential for Anti-Phosphatidylserine/Prothrombin Antibodies as a Criteria Test</b> Maria Laura Bertolaccini (UK)
<b>1.15 pm</b>	<b>Lupus Anticoagulant Testing: The Value of Dilute Russell’s Viper Venom Time (dRVVT) and Silica Clotting Time (SCT) Assays</b> Armando Tripodi (Italy)
Sponsored by INOVA Diagnostics & Instrumentation Laboratory	

**SEPTEMBER 22, 2016 – THURSDAY AFTERNOON SESSIONS**

<b>MAIN SESSION 3</b> Mechanisms of Antiphospholipid Antibody-mediated Pregnancy Morbidity		<b>DEEP DIVE SESSION 3</b> Direct Oral Anticoagulants and Antiphospholipid Syndrome	
<b>Moderators</b>	<b>Pier Luigi Meroni (Italy), Ware Branch (USA), Nergiz Yanmaz (Turkey)</b>	<b>Moderators</b>	<b>Ahmet Muzaffer Demir (Turkey), David Garcia (USA), Tom Ortel (USA)</b>
<b>Room</b>	<b>Hall A</b>	<b>Room</b>	<b>Hall B</b>
<b>1.30 pm</b>	<b>General Review – Mechanisms of aPL-mediated Pregnancy Morbidity and Potential Treatment Target</b> Jane Salmon (USA) (Online Presentation)	<b>1.30 pm</b>	<b>General Review of Direct Oral Anticoagulants (DOACs)</b> David Garcia (USA)
<b>1.55 pm</b>	<b>Antiphospholipid Antibody Internalisation into the Syncytiotrophoblast</b> Larry Chamley (New Zealand)	<b>2.00 pm</b>	<b>RAPS – Rivaroxaban in Antiphospholipid Syndrome (APS) - A prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic APS, with or without SLE</b> Hannah Cohen (UK)
<b>2.20 pm</b>	<b>Do Obstetric and Thrombotic aPL have Differential Effects Upon Target Cells?</b> Ian Giles (UK)	<b>2.15 pm</b>	<b>RAPS – Rivaroxaban in APS Pilot Trial Update - A Multicenter Feasibility Study of Rivaroxaban for Patients with APS and Prior Arterial or Venous Thrombosis</b> Mark Crowther (Canada)
<b>2.45 pm</b>	<b>Targeting β<sub>2</sub>-Glycoprotein-I to Prevent Obstetric APS</b> Pier Luigi Meroni (Italy)	<b>2.30 pm</b>	<b>TRAPS – Rivaroxaban in Thrombotic APS Trial Update - A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With APS</b> Vittorio Pengo (Italy)
<b>3.10 pm</b>	<b>Group Conclusions</b>	<b>2.45 pm</b>	<b>ASTRO APS - Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients with APS</b> Scott Woller (USA)
		<b>3.00 pm</b>	<b>Group Discussion</b>
<b>3.15 pm 3.45 pm</b>	<b>Coffee Break, Exhibition, and Poster Discussions</b>	<b>3.15 pm 3.45 pm</b>	<b>Coffee Break, Exhibition, and Poster Discussions</b>
Partially Sponsored by an Unrestricted Educational Grant from the Barbara Volcker Center for Women & Rheumatic Diseases at Hospital for Special Surgery, New York, NY, USA		Partially Sponsored by an Unrestricted Educational Grant from BAYER®	

MAIN SESSION 4 – Abstract Recognition Award (Innovation and Excellence) Presentations		DEEP DIVE SESSION 4 - Disease Activity, Damage, Risk Scores, and Quality of Life in APS	
Moderators	Graham Hughes (UK), Takao Koike (Japan)	Moderators	Mary Carmen Amigo (Mexico), Ihsan Ertenli (Turkey), Savino Sciascia (Italy)
Room	Hall A	Room	Hall B
3.45 pm	<b>OP01 - Gram Negative Bacterial Inflammation Ameliorated by the Plasma Protein <math>\beta_2</math>-Glycoprotein-I</b> <u>Bill Giannakopoulos (Australia)</u> , Saijun Zhou, Gang Chen, Miao Qi1, Fatima El-Assaad, Steve A Krilis	3.45 pm	<b>Introduction &amp; the Importance of Damage and Risk Measurement in APS</b> Mary-Carmen Amigo (Mexico)
4.00 pm	<b>OP02 - Identification of Novel Genetic Susceptibility Loci in Primary APS</b> Elizabeth Gensterblum, Travis Hughes, Manuel Martínez-Bueno, Maria Orietta Borghi, Guillermo Pons-Estel, Gerard Espinosa, Alexandra Zhernakova, Cisca Wijmenga, Ricard Cervera, Pier Luigi Meroni, Marta E Alarcón-Riquelme, <u>Amr H Sawalha (USA)</u>	4.00 pm	<b>Damage Index in APS</b> Ma. Victoria Goycochea-Roblec (Mexico)
4.15 pm	<b>OP03 – Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic aPL in a Thrombosis Mouse Model</b> <u>Rohan Willis (USA)</u> , Elizabeth Papalardo, Zurina Romay-Penabad, Premkumar Christadoss, Chella David, Ana Laura Carrera-Marin, Elba Reyes-Maldonado, Rajani Rudrangi, Ethel Garcia-Latorre, Miri Blank, Allan R Brasier, Emilio B Gonzalez	4.15 pm	<b>Antiphospholipid Score: A Quantitative Index for Diagnosis of APS and Predictive Marker of Thrombosis.</b> Tatsuya Atsumi (Japan)
4.30 pm	<b>OP04- Antiphospholipid Syndrome Neutrophils are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target</b> <u>Jason S Knight (USA)</u> , Patrick Coit, He Meng, Srilakshmi Yalavarthi, Paul Renauer, Robert C Grenn, Levi F Mazza, Hui Wang, Daniel T Eitzman, Amr H Sawalha	4.30 pm	<b>Global APS Score (GAPSS)</b> Savino Sciascia (Italy)
4.45 pm	<b>OP05 - Antiphospholipid Antibody-Mediated Increase of Tissue Factor in Arterial Wall is Associated with Increased Thrombus Size in a Mouse Model</b> <u>Rohan Willis (USA)</u> , Pierre Grant, Zurina Romay-Penabad, Elizabeth Papalardo, Mohammed Jamaluddin, Rajani Rudrangi, Emilio Gonzalez, Allan R Brasier	4.45 pm	<b>Can We Measure APS Disease Activity?</b> Anisur Rahman (UK)
5.00 pm	<b>OP06 - Levels of Cell-bound C4d in Primary APS in Comparison to SLE</b> <u>Maria Gerosa (Italy)</u> , Paola Lonati, Francesca Rovelli, Tania Ubiali, Paolo Macor, Maria Orietta Borghi, Pier Luigi Meroni	5.00 pm	<b>Quality of life in APS</b> Stephane Zuily (France)
5.15 pm	<b>OP07 - A Patient-derived Autoimmune IgG Type Monoclonal Anticardiolipin Antibody that Binds to <math>\beta_2</math> Glycoprotein Domain I but not to Total <math>\beta_2</math> Glycoprotein-I Molecule</b> <u>Kenji Oku (Japan)</u> , Yuusaku Kanetsuka, Kazumasa Ohmura, Masaru Kato, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda, Gary L Norman, Bas deLaat, Tatsuya Atsumi	5.15 pm	<b>Group Discussion</b>
5.30 pm	Closure	5.30 pm	Closure